Now your pump is reduced to $800k revenues? You gave up on the $1.5M revenue pump?
LOL what a coward.
You say $800K "would be a significant improvement over the $700k-ish reported in each of the last two years." Significant? Really? Another $25K per quarter?
Sorry, but $800K would SUCK because all your BIEL catalysts -- VA, Taiwan, Veterinary -- began in 2024. $800K would mean those catalysts are just hype.
You also pump that "Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc." That is ALL bullshit. Let's look at each:
"new FDA clearances" -- for what? They already have full-body OTC clearance for pain. They don't have any pending FDA applications or pending clinical trials that would require a new 510(k). Thumb Study? that's just pain. Phantom pain? Maybe in ten years -- that's how long it would take Ilfeld to finish a clinical trial to follow up on his Pilot Study.
"vagus nerve patent?" for one thing, that would be years down the road, but more critical: doctors, researchers, and wellness companies have been using PEMF for vagus nerve applications for YEARS. BIEL can't patent the use of PEMF on the vagus nerve -- they can only patent the use of THEIR DEVICE on the vagus nerve, and WHO CARES without human trials.
"NPA?" Do you mean the NOPAIN Act? Aren't you aware that BIEL's devices aren't covered by the NOPAIN Act? To be covered by the NOPAIN Act, devices and drugs need to be reimbursed under Medicare and they need proof that the drug/device reduces opioid use. BIEL has neither of those things. The Ilfeld Opioid Trial was an abject failure. Furthermore, the NOPAIN Act is only for three years, 2025-2027, so if BIEL wants to catch up on the requirements, time is fast running out.
"UK/Australia, New Zealand, etc?" You're really scraping the bottom of the barrel here. BIEL has had distributors in the UK, Australia, and New Zealand for a dozen years.
"RecoveryRx Veterinary international sales?" You're putting the cart in front of the horseshit here. Your US Veterinary Sales pump hasn't come through yet, especially if 2024 revenues are only $800K.
Face it -- the only way BIEL participates in an "OTC Run" is if EVERY OTC biotech runs, like in 2021 when BIEL was just one of many OTC biotechs that had price spikes. If it happens, it will have nothing to do with any of the hype you're pumping. So why not just give it a rest.
BTW, Robinhood is NOT "[the] favorite for OTC investors" because RobinHood won't let you trade penny stocks. How could you not know that? RobinHood was the reason that the 2021 OTC rally wasn't as big, and didn't last as long, as the 2008-2009 OTC run. That 2008 run was epic, and it's because RobinHood wasn't around -- RobinHood started in 2013.
BIEL
Market Data 
Markets 
AI
